tiprankstipranks
Trending News
More News >
ANGLE PLC (GB:AGL)
LSE:AGL
UK Market
Advertisement

ANGLE plc (AGL) Earnings Dates, Call Summary & Reports

Compare
36 Followers

Earnings Data

Report Date
Apr 23, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.02
Last Year’s EPS
-0.02
Same Quarter Last Year
Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Sep 09, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
ANGLE's earnings call presented a balanced outlook with significant achievements in pharma collaborations and technology development, but also faced challenges from adverse market conditions affecting revenue and the need for additional funding.
Company Guidance
During the ANGLE 2025 Interim Results Call, CEO Andrew Newland provided comprehensive guidance on the company's financial and operational progress for the first half of the fiscal year. Despite facing adverse market conditions that pressured revenue, with pharma revenue down and product revenue flat compared to the prior year, ANGLE has made significant strides in commercialization and development. Key achievements include the completion of three major pharma projects with Eisai and AstraZeneca, the development of the DNA dual analysis using Illumina's NGS assay, and the commencement of a collaboration with Myriad Genetics for large-scale commercialization of the Parsortix system. The company has maintained tight cost control, reducing operating expenditure by 12%, and holds a cash position of GBP 6.6 million, with a runway extending into Q1 2026. Despite the challenging environment, ANGLE anticipates further developments with multiple large pharma and med tech companies and is actively pursuing additional funding sources to ensure continued growth and innovation in its cancer diagnostic solutions.
Successful Completion of Large Pharma Projects
ANGLE successfully completed three large pharma projects with Eisai and AstraZeneca, demonstrating the utility of the Parsortix system in HER2 breast cancer trials and developing assays for DNA Damage Response and Androgen Receptor.
MedTech Collaboration with Myriad Genetics
ANGLE announced its first large medtech collaboration with Myriad Genetics, offering potential for large-scale commercialization of the Parsortix system.
Development of DNA Dual Analysis
A major achievement was the development of the DNA dual analysis, Illumina, end-to-end NGS assay, which identifies twice as many mutations as ctDNA alone.
Accreditation Progress for Clinical Lab
ANGLE is making good progress on accrediting its clinical lab, targeting completion by the end of the year, which would enable offering tests directly for patient management.

ANGLE plc (GB:AGL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GB:AGL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 23, 2026
2025 (Q4)
-0.02 / -
-0.02
Sep 09, 2025
2025 (Q2)
- / -0.03
-0.0290.00% (0.00)
May 28, 2025
2024 (Q4)
- / -0.02
-0.0450.00% (+0.02)
Sep 26, 2024
2024 (Q2)
- / -0.03
-0.03823.68% (<+0.01)
Jun 05, 2024
2023 (Q4)
- / -0.04
-0.04918.37% (<+0.01)
Sep 07, 2023
2023 (Q2)
- / -0.04
-0.0392.56% (<+0.01)
Apr 21, 2023
2022 (Q4)
- / -0.05
-0.031-58.06% (-0.02)
Sep 29, 2022
2022 (Q2)
- / -0.04
-0.036-8.33% (>-0.01)
Apr 28, 2022
2021 (Q4)
- / -0.03
-0.03818.42% (<+0.01)
Sep 30, 2021
2021 (Q2)
- / -0.04
-0.028-28.57% (>-0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:AGL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Sep 09, 2025
5.75p4.15p-27.83%
May 28, 2025
9.75p8.00p-17.95%
Sep 26, 2024
10.75p8.70p-19.07%
Jun 05, 2024
17.97p15.47p-13.91%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ANGLE PLC (GB:AGL) report earnings?
ANGLE PLC (GB:AGL) is schdueled to report earning on Apr 23, 2026, TBA (Confirmed).
    What is ANGLE PLC (GB:AGL) earnings time?
    ANGLE PLC (GB:AGL) earnings time is at Apr 23, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of ANGLE PLC stock?
          The P/E ratio of ANGLE plc is N/A.
            What is GB:AGL EPS forecast?
            GB:AGL EPS forecast for the fiscal quarter 2025 (Q4) is -0.02.
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis